Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising potential medicines, and there are more and more flavors of ...

Gene therapies promise life-saving medicines, but their uptake has been slow and recent investments in the modality and supporting technologies have lagged across the biopharmaceutical industry. Dr.

Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule programs were built around inhibition. A compound was expected to bind a ...

The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...

Ingenix's Biological Reasoning Engine fuses biological data through Modality Fusion, a new architecture for AI in drug development. In a recent oncology engagement, the Biological Reasoning Engine ...

Drug discovery is entering a new phase of complexity. From peptides and oligonucleotides to targeted protein degraders and other emerging modalities, many of today’s therapies require advanced ...